MN-001, a potential treatment for idiopathic pulmonary fibrosis (IPF), will soon have patent protections in China. MediciNova, the company developing MN-001 (tipelukast), received a Notice of Allowance from the Chinese Patent Office, which means that the company’s application fulfills all necessary requirements. Once issued, the patent is expected to…
The idiopathic pulmonary fibrosis (IPF) treatment candidate BBT-877 is safe and well-tolerated in healthy volunteers, and markedly reduced the plasma levels of a lipid molecule involved in inflammation and fibrosis, according to results of a Phase 1 clinical trial. The research, “BBT-877, a potent Autotaxin…
Ofev (nintedanib) reduced lung function decline by more than 50% in patients with progressive fibrosing interstitial lung diseases (ILDs), data from a Phase 3 trial show. The findings were presented in a poster at the recent European Respiratory Society (ERS) International Congress in Madrid, Spain, and simultaneously…
Blade Therapeutics will expand its pipeline in the field of fibrotic diseases with the acquisition of Atxco and its lead candidate PAT-409, which is ready to enter Phase 1 clinical studies. PAT-409 was engineered to specifically inhibit the autotaxin enzyme involved in the production of a fatty molecule called…
Blocking the activity of interleukin-11 (IL-11) — a molecule that mediates immune and inflammatory responses — reverses tissue scarring, or fibrosis, in the lungs of mice with idiopathic pulmonary fibrosis (IPF), a study has found. The findings of the study, “Interleukin-11 is a therapeutic target in idiopathic…
Different combinations of medications to manage comorbidities (additional conditions) may influence disease progression in people with idiopathic pulmonary fibrosis (IPF), a study suggests. The study, “Concomitant Medications and Clinical Outcomes in Idiopathic Pulmonary Fibrosis,” was published in the European Respiratory Journal. IPF is a complex…
Next month’s annual conference of the National Organization for Rare Disorders (NORD) in Washington, D.C., couldn’t come at a better time, says Marshall Summar, MD, chairman of NORD’s board of directors. “The pace of discovery in rare diseases has gone from brisk to hypersonic,” Summar told Bionews Services, publisher…
A small RNA molecule called miR-133a can prevent tissue scarring (fibrosis) in people with idiopathic pulmonary fibrosis (IPF) by interfering with a pro-fibrotic signaling pathway that is involved in disease progression, a study says. The findings of the study, “Transforming growth factor (TGF)-β1-induced miR-133a inhibits myofibroblast differentiation…
Weight loss is more common among patients with idiopathic pulmonary fibrosis (IPF) who are being treated with Ofev (nintedanib), and also among those at advanced stages of the disease. A study with that finding, “Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary…
A mutation in the gene ZCCHC8 leads to abnormalities in the structure of telomeres, the protective caps at the end of the DNA, leading to the development of idiopathic pulmonary fibrosis (IPF), a new study shows. The study, titled “ZCCHC8, the nuclear exosome targeting component, is…
Get regular updates to your inbox.
